Market closedNon-fractional
Arcturus Therapeutics Holdings/ARCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
Ticker
ARCT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
180
Website
arcturusrx.com
ARCT Metrics
BasicAdvanced
$619M
Market cap
-
P/E ratio
-$4.02
EPS
2.76
Beta
-
Dividend rate
Price and volume
Market cap
$619M
Beta
2.76
Financial strength
Current ratio
3.256
Quick ratio
2.733
Long term debt to equity
10.475
Total debt to equity
12.093
Interest coverage (TTM)
-5,107.17%
Management effectiveness
Return on assets (TTM)
-17.22%
Return on equity (TTM)
-36.17%
Valuation
Price to revenue (TTM)
4.929
Price to book
2.34
Price to tangible book (TTM)
2.34
Price to free cash flow (TTM)
62.854
Growth
Revenue change (TTM)
-55.69%
Earnings per share change (TTM)
-198.54%
3-year revenue growth (CAGR)
139.89%
3-year earnings per share growth (CAGR)
-7.65%
What the Analysts think about ARCT
Analyst Ratings
Majority rating from 9 analysts.
ARCT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$38M
23.38%
Net income
-$27M
129.06%
Profit margin
-70.52%
85.68%
ARCT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.98
-$0.61
-$0.32
-$1.00
-
Expected
-$0.21
-$1.69
-$0.99
-$1.19
-$1.58
Surprise
839.50%
-63.94%
-67.75%
-15.88%
-
ARCT News
AllArticlesVideos
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
Business Wire·1 week ago
Arcturus: A Hidden Gem In The Biotech Sector
Seeking Alpha·2 months ago
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcturus Therapeutics Holdings stock?
Arcturus Therapeutics Holdings (ARCT) has a market cap of $619M as of July 27, 2024.
What is the P/E ratio for Arcturus Therapeutics Holdings stock?
The price to earnings (P/E) ratio for Arcturus Therapeutics Holdings (ARCT) stock is 0 as of July 27, 2024.
Does Arcturus Therapeutics Holdings stock pay dividends?
No, Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Arcturus Therapeutics Holdings dividend payment date?
Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings (ARCT) has a beta rating of 2.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Arcturus Therapeutics Holdings stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.